ArticleCancer management and research2026
Preoperative Lactate Dehydrogenase-to-Albumin Ratio and Overall Survival in Gastric Cancer: Stage-Specific Prognostic Implications.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the prognostic value of the preoperative serum lactate dehydrogenase-to-albumin ratio (LAR) in patients with gastric cancer (GC), with a focus on its stage-specific implications for overall survival (OS). Methods: This single-center retrospective cohort study included 568 patients with resected GC. Patients were categorized into low-LAR and high-LAR groups for comparative analysis. The baseline characteristics, short-term postoperative outcomes, and OS were compared between the two groups. Cox proportional hazards regression was performed to identify the independent risk factors for OS. Kaplan-Meier analysis was used to assess OS across tumor stages in the two LAR groups. Results: In total, 568 patients were enrolled. Patients in the high-LAR group were older and had a lower body mass index (BMI), while also showing higher preoperative lactate dehydrogenase level, lower albumin level, and a greater number of retrieved lymph nodes. Univariate and multivariate analyses indicated that BMI was independently associated with a favorable OS. Tumor stage and preoperative neoadjuvant treatment were identified as independent adverse prognostic factors for OS. However, LAR was not independently associated with OS in the entire cohort. The unadjusted Kaplan-Meier analysis showed that patients in the high-LAR group had poorer OS in the overall cohort and in stage II GC, indicating a potential stage-specific prognostic relevance of LAR. Conclusion: Preoperative LAR was not an independent prognostic factor for overall OS in the GC cohort. However, exploratory analyses suggested potential stage-specific prognostic relevance, particularly in stage II GC. Further large-scale prospective studies are required to validate these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.